Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Clopidogrel versus ticlopidine after intracoronary stent placement
Autore:
Berger, PB; Bell, MR; Rihal, CS; Ting, H; Barsness, G; Garratt, K; Bellot, V; Mathew, V; Melby, S; Hammes, L; Grill, D; Holmes, DR;
Indirizzi:
Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Rochester, MN 55905 USA Mayo Clin & Mayo Fdn Rochester MN USA 55905 Dis, Rochester, MN 55905 USA Mayo Clin & Mayo Fdn, Biostat Sect, Rochester, MN 55905 USA Mayo Clin & Mayo Fdn Rochester MN USA 55905 Sect, Rochester, MN 55905 USA
Titolo Testata:
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
fascicolo: 7, volume: 34, anno: 1999,
pagine: 1891 - 1894
SICI:
0735-1097(199912)34:7<1891:CVTAIS>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
ANTIPLATELET THERAPY; ASPIRIN; ANTICOAGULATION; IMPLANTATION; TRIAL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Berger, PB Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA Mayo Clin & Mayo Fdn 200 1st St SW Rochester MN USA 559055 USA
Citazione:
P.B. Berger et al., "Clopidogrel versus ticlopidine after intracoronary stent placement", J AM COL C, 34(7), 1999, pp. 1891-1894

Abstract

OBJECTIVES The study compared the safety and efficacy of ticlopidine with clopidogrel in patients receiving coronary stents. BACKGROUND Stent thrombosis is reduced when ticlopidine is administered with aspirin. Clopidogrel is similar to ticlopidine in chemical structure andfunction but has fewer side effects; few data are available about its use in stent patients. METHODS We compared 30-day event rates in 500 consecutive coronary stent patients treated with aspirin and clopidogrel (300 mg loading dose immediately prior to stent placement, and '75 mg/day for 14 days) to 827 consecutivestent patients treated with aspirin and ticlopidine (500 mg loading dose and 250 mg twice daily for 14 days). RESULTS Patients treated with clopidogrel had more adverse clinical characteristics including older age, more severe angina, and more frequent infarction within the prior 24 h. Nonetheless, mortality was 0.4% in clopidogrel patients versus 1.1% in ticlopidine patients; nonfatal myocardial infarction occurred in 0% versus 0.5%, stent thrombosis in 0.2% versus 0.7%, bypass surgery or repeal angioplasty in 0.4% versus 0.5%, and any event occurred in 0.8% versus 1.6% of patients, respectively (p = NS). Based on the observed 30-day event rate of 1.6% with ticlopidine, the statistical power of the study was 43% to detect an even rate of 0.5% with clopidogrel, and 75% to detect an event rate with of 4% with clopidogrel, with a p value of 0.05. CONCLUSIONS These data indicate that clopidogrel can be safely substitutedfor ticlopidine in patients receiving coronary stents. (C) 1999 by the American College of Cardiology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/07/20 alle ore 22:34:43